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We measured the growth hormone (GH) response to clonidine (an alpha-2-adrenergic
agonist) and to apomorphine (a dopaminergic agonist) in 15 major endogenous and 15
minor depressive in-patients matched for gender and age. Results showed a significantly
smaller GH response in the major depressives to both clonidine (P< 0.01) and apomorphine
(P< 0.001). No significant difference existed between the two groups with regard to
changes in blood pressure and pulse rate during either test. While major depressives
showed a trend toward smaller sedative side-effects than minor depressives after
clonidine, they showed significantly smaller sedative and gastro-intestinal side-effects
after apomorphine. No significant correlation was present either in the major depressive
or in the minor depressive group between the GH responses following clonidine and
apomorphine challenges. These results support the hypothesis of both noradrenergic and
dopaminergic neurotransmitter disturbances in major depression, with individual variability
with regard to those biochemical anomalies.
Neuroendocrine strategy may provide an indirect
index of central neurotransmission which is particu
larly interesting in biological psychiatry. Indeed, the
release of anterior pituitary hormones depends on
hypothalamic releasing factors, the secretion of
which is controlled by neurotransmitters also impli
cated in mental illnesses. The greatest amount of
information on this can be obtained from the study
of growth hormone (OH) response to specific
pharmacological challenges: indeed, OH secretion is
stimulated by dopamine, noradrenaline through
alpha receptors, and possibly serotonin, while it is
inhibited by noradrenaline through beta receptors
and by gamma-aminobutyric acid (OABA) (Checkley,
1980).
The current main pathophysiological theory of
endogenous depression hypothesises a decreased
activity in central neurotransmitter systems: nor
adrenergic, serotonergic, and possibly dopaminergic
(Willner, 1985). These disturbances could result from
a diminished neurotransmitter release or, as suggested
more recently, from disturbances in the â€˜¿sensitivity'
of specific receptors. Possible central catechol
aminergic disturbances in depressive disorders have
been assessed by the study of the OH response to
various pharmacological challenges such as ampheta
mine, clonidine, desipramine, L-dopa, apomor
phine, and carbidopa (Checkley, 1980).
With regard to noradrenergjc receptors, most
studies, although using poorly specific pharmaco
logical challenges (i.e. amphetamine or desipramine),
converge to suggest a smaller OH response among
major depressive patients (Siever & Uhde, 1984). In
comparison with those pharmacological agents,
clonidine exhibits a more specific alpha-2-adrenergic
agonistic activity and stimulates OH secretion
through postsynaptic alpha-2-adrenergic receptors in
the hypothalamus (Lal & Martin, 1980; Siever eta!,
1982). This clonidine-induced OH response appears
to be blunted among major depressive patients
(Matussek et al, 1980; Checkley et a!, 1981, 1984;
Siever et a!, 1982; Chancy et al, 1982; Siever &
Uhde, 1984; Boyer et a!, 1986), supporting an
alpha-2-adrenergic receptor disturbance in major
depressive disorders.
Various lines of evidence also suggest a role for
dopamine in the pathophysiology of depression
(Willner, 1985); but the studies of OH response to
dopaminergic agonists such as L-dopa or apomor
phine have failed to show any differences for major
depressive patients (Sachar et a!, 1975; Casper &
Davis, 1977; Maany et al, 1979; Linkowski et a!,
1983;Cornet al, 1984a; Jimerson eta!, 1984; Meltzer
et a!, 1984). However, it should be noted that most
studies have used L-dopa, which has a low priority
potency or specificity. Moreover, most results should
be interpreted with caution because the samples of
depressive patients and control subjects differed with
regard to age, gender, and endocrine status in
women, all factors which modify the reactivity to
dopaminergic agonists (Ettigi et a!, 1975). In
comparison with L-dopa, apomorphine appears to
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be a more specific and more potent dopaminergic
agonist and induces OH release in a more reprodu
cible way (Rotrosen et a!, 1976, 1979; La Rossa
et a!, 1977; Lal & Martin, 1980; Costain et a!,
1982).
In this context, the purpose of our study was to
compare the OH response after clonidine and
apomorphine challenges in two samples of major
depressive and minor depressive patients matched for
gender and age. We wanted to verify if major
depression was associated with disturbances in
alpha-2-adrenergic or dopaminergic receptors and to




Clonidine and apomorphine challenge tests were performed
in this order according to the same procedure with an
interval of at least two days between the tests.
At 07:00, after an overnight fast, an indwelling catheter
was inserted in a forearm vein. Blood samples of 10ml were
collected every 20 minutes from 40 minutes before to 120
minutes after injection, at 08:00, of either clonidine
(0.15 mg diluted in saline to obtain 20 ml intravenously in
ten minutes), or apomorphine (0.5 mg diluted in saline to
obtain 0.5 ml subcutaneously).
After each blood sampling, blood pressure, pulse rate
and sedative and gastro-intestinal side-effectswere recorded.
In addition, at the end of the procedure, sedative and gastro
intestinalside-effectsweregloballyrated accordingto a six
point scale by a research nurse blind to diagnosis. The level
of alertness was rated according to the following scores:
0= no change; 1= very slight drowsiness; 2 = slight drowsi
ness; 3= drowsiness; 4= important drowsiness; 5= sleep.
Gastro-intestinal reactions were rated according to the
following scores: 0 = no reaction; 1= slight and transitory
nausea; 2= nausea; 3= strong nausea without vomiting;
4 = vomiting; 5= severe vomiting.
GH assay
OH was measured with a double antibody radioimmuno
assay (Franchimont, 1968), with intra- and inter-assay
coefficients of variation of respectively 13.3 Â±4.7% and
14.8Â±9.6% and a detection limit of 0.2 ng/ml.
Data analysis
OH responses following clonidine and apomorphine were
assessed by two different methods: by OH peak values
following injection and by the areas under the curve situated
between injection (tO) and the last blood sampling
(tl2O mm). Both analyses were performed using absolute
OH values as well as differences related to basal (tO) levels
(relative values). Since the correlations between absolute
and relative values (assessed by Pearson's correlation
coefficient) were very high (r>O.98), only the absolute
valuesarereportedhere.
Changes over time in blood pressure and pulse rate were
assessed by variance analysis (ANOVA) with repeated
measures. OH responses and sedative and gastro-intestinal
side-effects in major and minor depressives were compared
using paired t-tests. Since some variances were high
compared with mean values, the comparison was also
performed by means of the Wilcoxon non-parametric test.
The relationship between individual OH responsesafter
clonidine and apomorphine as well as the relationships
between OH response and sedativeand gastro-intestinal side
effects were assessed by Pearson's correlation coefficient.
aoaldine test
Method
Fifteen in-patients consecutively admitted to the Biological
Psychiatry and Psychopharmacology Unit of the University
Hospital of Liege, Belgium, were included in the study.
They met Research Diagnostic Criteria for major depressive
disorder, endogenous subtype. Moreover, they had a score
of at least 6 on the Newcastle index for endogenous
depressionand of at least 20 on the Hamilton depression
scale at the end of a drug-free period of at least two weeks.
All patients were unipolar and none of them exhibited
psychotic features. This sample comprised seven male and
eight female patients, aged 26-61 years (mean age =
45.2 Â±11.3). Their individual characteristics are presented
in Table I.
These patients were matched for gender, age (within three
years) and, in the case of women, menopausal status with
15 in-patients meeting Research Diagnostic Criteria for
minor depression, having a score less than 6 on the
Newcastle index and less than 20 on the Hamilton
depression scale (Table I). Weight ranges were 62â€”81kg
for major depressives (mean weight = 69.5 kg Â±7.0) and
61-76 kg for minor depressives(mean weight=69.8 kgÂ±7.4),
without significant differences between the two groups
(t=0.l, d.f.=28, NS).
Diagnosticprocedureswereperformedindependentlyby
two research psychiatrists blind to neuroendocrine test
results. All patients were free of medical illness as
evidenced by history, medical examination, ECG, chest
X-ray, EEG, and routine laboratory tests. They had
also been free of drugs, includingbenzodiazepines,for at
least two weeks at the time of the study. The neuro
endocrine tests were performed between the third and
the twelfth day of the menstrual cycle in pre-menopausal
women (four in each group: patients 1, 3, 5, 7 and 16, 18,
20, 22). Patients with a basal systolicblood pressure less
than 100 mmHg were excluded from the study. Moreover,
in order to be included, patients had to present basal (tO)
GH level less than 5 ng/ml before both pharmacological
challenges (Ansseau et al, 1984). All patients were fully




among the 15major and the 15minor depressivepatients
















67RESPONSE OF GROWTH HORMONE TO CLONIDINE AND APOMORPHINE
TABLE I
Characteristicsof thesample and individualresponsestoclonidineand apomorphine challenges
1. Major = major depression; Minor = minor depression; end. = endogenous; UP = unipolar.
20 r
0'
matched for gender and age are presented in Fig. 1.
Individual endocrine and clinical data are shown in Table I.
Major depressives exhibited a significantly lower OH
response than minor depressives: for peak values,
4.OÂ±6.8ng/mlvsll.7Â±7.5ng/ml,z= â€”¿3.3,P<O.O1,and
for the areas under the response curve, 301 Â±538 ng mm/mI
vs 653Â±424ngmin/ml, z=2.9, P<O.Ol.
Blood pressure exhibited a significant decrease following
clomdine for the whole sample (F(6, 168)= 16.4,
P<0.0000l for systolic blood pressure, and F(6, l68)=5.5,
P<O.0005 for diastolic blood pressure), but without
significant difference between major and minor depressives
(F(1, 28)= 0.5, NS for systolic blood pressure, and F(1,
28)= 0.1, NS for diastolic blood pressure). Pulse rate did
not show any significant change.
Ratings of sedative effects exhibited a trend toward lesser
severity among major depressive than among minor
depressive patients (1.6 vs 2.7, U= â€”¿1.8, P=O.07). No
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FIG. I Changes over time in mean GH level (Â±s.d.) following
clonidine (0.15 mg i.v.)in 15major (â€”4) and 15minor(Uâ€”U)
depressivepatients.
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Relationship between GH responses
foHowingclonidine and apomorphine
No significant correlation was present between individual
OH peaks following clonidine and apomorphine among
major depressiveor minor depressivepatients (r= 0.11 for
major depressives and r = 0.06 for minor depressives).
However, if both subgroups were pooled together, a slightly
significant relationship existed (r=O.36, d.f. =28, P<O.05).
Discussion
Concerning the clonidine test, the results of our study
show a smaller OH response in major depressive as
compared with minor depressive patients. These
results are in agreement with previous studies
comparing the OH response to clonidine in major
depressive patients and normal controls (Matussek
eta!, 1980; Checkley eta!, 1981; Chancy eta!, 1982;
Siever eta!, 1982; Siever & Uhde, 1984; Boyer eta!,
1986) or reactive depressives (Checkley eta!, 1984).
The only negative report used oral clonidine in a
small sample of seven endogenous and seven non
endogenous depressive patients (Dolan & Calloway,
1986); it is unclear if 0.15 mg of oral clonidine is able
to consistently stimulate OH release over a two-hour
period. These findings suggest a hyposensitivity
of postsynaptic alpha-2-adrenergic hypothalamic
receptors in major depression, since OH response to
clonidine seems to depend on the stimulation of those
receptors (review in Siever et a!, 1982).
The lack of difference between major and minor
depressives with regard to hypotensive response
following clonidine is in agreement with three
previous studies showing similar changes in blood
pressure among major depressives and normal
controls (Checkley eta!, 1981; Siever & Uhde, 1984;
Siever et a!, 1984). The lack of global modification
of pulse rate following clonidine also confirms the
study of Checkley et a! (1981). However, Siever &
Uhde (1984) and Siever et a! (1984) found a smaller
decrease in pulse rate in major depressives than in
normal subjects. It should be noted, however, that
besides the classical mechanism explaining clonidine
induced hypotension by a stimulation of alpha-2-
adrenergic receptors in the brain areas responsible
for cardiovascular control, various lines of evidence
suggest a role for H2 histaminic receptors (review in
Pettinger, 1980).
The trend toward smaller sedative side-effects in
the major depressive group is in agreement with the
hypothesis of a central noradrenergic hyposensitivity.
However, Checkley et a! (1981) did not find any
significant difference between major depressives and
normal subjects in the changes over time of sedative
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FIG. 2 Changes over time in mean GH level (Â±s.d.) following
apomorphine (0.5 mg s.c.) in 15 major (*â€”) and 15 minor
(S-â€”U) depressive patients.
OH responsesand ratingsof sedativereactions(r= â€”¿0.17,
d.f.=28, NS).
Apomorphine test
The changes over time in mean OH level following
apomorphine among the 15 major and the 15 minor
depressive patients are presented in Fig. 2. Individual
endocrine and clinical data are shown in Table 1. Major
depressive patients exhibited a significantly lower OH
response than minor depressives: 5.3 Â±3.8 ng/ml vs
20.4Â±12.7 ng/ml, z=3.5, P<O.OO1 for peak values, and
281 Â±159ng min/ml vs 1134Â±745 ng min/ml, z=3.7,
P< 0.001 for the areas under the response curve.
Blood pressure exhibited a significant decrease for
the whole sample (F(6, l68)= 3.2, P<O.05 for systolic
blood pressure, and F(6, 168)= 2.8, P<O.O5 for diastolic
blood pressure), without significant difference between
the two groups (F(1, 28)= 0.5, NS for systolic blood
pressure, and F(l, 28)= 3.0, NS for diastolic blood
pressure).Pulserate did not exhibitany significantchanges
over time.
Ratings of both gastro-intestinal and sedative side
effects were significantly lower among major as compared
with minor depressives (respectively 1.0 vs 2.6, U= 2.7,
P<O.Ol, and 0.5 vs 2.1, U=2.7, P<0.Ol). While the
relationshipsbetweengastro-intestinalside-effectsand OH
responseand betweensedativeside-effectsand OH response
werenot significantin eitherof the twoisolatedgroups(for
gastro-intestinal reactions, r = â€”¿0.20 among major
depressives and r= 0.29 among minor depressives; for
sedative reactions, r=O.29 among major depressives and
r = 0.11 among minor depressives), these relationships
became significant when the whole sample was included in
the analysis (r=O.42, d.f. = 28, P<O.05 for gastro-intestinal
reactions, and r=O.40, d.f. =28, P.czO.O5 for sedative
reactions).
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by the subject every 15 minutes. It should be noted
that the mechanism of the sedative effect induced
by clonidine is most probably of noradrenergic
origin; a possible interpretation of these sedative
effects in muscarinic receptor or H2 histaminic
receptor stimulation did not find experimental
support (Spyraki & Fibiger, 1982).
Following apomorphine, major depressive patients
also exhibit a smaller OH response as compared with
minor depressive patients. These results, which
suggest a hyposensitivity of dopaminergic hypo
thalamic receptors controlling OH release in major
depression, disagree with previous reports. Most
studies have used L-dopa without finding disturb
ances in OH response in unipolar depressive patients
(Sachar et a!, 1975; Maany et a!, 1979; Linkowski
et a!, 1983). It should be noted, however, that
L-dopa has a low dose of specificity for the
dopamine receptors and that it is not demonstrated
that L-dopa-induced OH response depends on
dopaminergic receptor stimulation. Indeed, this
release is inhibited not only by chlorpromazine, a
dopaminergic receptor antagonist, but also by phen
tolamine, an alpha-adrenergic antagonist, and by
cyproheptadine, a serotonergic antagonist; more
over, L-dopa-induced OH response is increased by
propanolol, a beta-blocker (review in Lal & Martin,
1980). Compared to L-dopa, apomorphine seems to
induce OH secretion by more specifically dopa
minergic mechanisms. Indeed, apomorphine-induced
OH release is only inhibited by pharmacological
agents exhibiting dopaminergic antagonist properties
(neuroleptics), such as chlorpromazine, halopendol,
pimozide, sulpiride, or clozapine (review in Lal &
Martin, 1980). Moreover, apomorphine appears a
much more potent and reproducible stimulus of OH
secretion than L-dopa. In three studies where OH
responses to apomorphine (0.75 mg subcutaneously)
and L-dopa (500mg orally) were compared in the
same normal subjects, apomorphine induced a OH
response in all 26 subjects, while L-dopa was only
effective in 16 subjects (62%) (Lal et a!, 1975;
Rotrosen et a!, 1976; La Rossa et a!, 1977). More
over, the OH response is highly reproducible in the
same subjects if the test is repeated (Rotrosen et a!,
1979; Costain et a!, 1982).
Few studies have used apomorphine-induced OH
stimulation in depressive patients, and none has
shown differences with normal subjects (Casper &
Davis, 1977; Maany eta!, 1979; Jimerson eta!, 1984;
Meltzer eta!, 1984). A possible explanation for these
negative results is the use in these studies of an
apomorphine dose of 0.75 mg rather than 0.50mg
as in our study. A 0.75 mg dose could be potent
enough to induce a complete OH response even in
case of relative hyposensitivity of hypothalamic
receptors.
Recently, Corn eta! (l984a) performed clonidine
and apomorphine challenges in the same@eight
patients with endogenous depression and found
significantly lower OH response following clonidine
than following apomorphine. However, no control
group was included in this study and the selection
of the doses of clonidine (1.3 pg/kg) and apo
morphine (0.005 mg/kg) was based on small studies
in different groups of normal subjects (Costain eta!,
1982; Corn et a!, 1984b) which showed striking
interpatient variability in the OH response.
The relative hyposensitivity of dopamine receptors
in major depressives as compared with minor
depressives is confirmed by the major depressives'
lower rate of sedative and gastro-intestinal side
effects induced by apomorphine. These effects have
never before been specifically assessed in depressive
patients.
We can interpret the blunted OH response to
clonidine and apomorphine as indirect evidence for
both noradrenergic and dopaminergic abnormalities
in endogenous depression. However, an alternative
and even more simple explanation could be that
endogenous depressive patients exhibit disturbances
in OH production or secretion itself (review in
Matussek, 1988). Supporting this hypothesis, a recent
study demonstrated lower spontaneous OH secretion
over a four-hour period in endogenous depressive
patients as compared with neurotic depressive
patients and normal subjects (Boyer et a!, 1986).
However, a previous report of 24-hour profile of
plasma OH concentrations showed diurnal hyper
secretion of OH in major depressive patients as
compared with normal subjects (Mendlewicz et a!,
1985). In our study, no difference in OH secretion
between major and minor depressive patients was
present over the 40 minutes preceding clonidine or
apomorphine injection.
Whether the blunted OH response to the various
tests in endogenous depression is due to a OH
releasing factor (ORF) deficit is uncertain. Cerebro
spinal fluid ORF levels in bipolar patients were found
to be the same as in controls (Berrettini et a!,
1987), but several recent preliminary studies testing
the OH response to ORF yielded controversial
results. Eriksson (1985) and Krishnan et a! (1986)
found a significantly higher OH peak response
to ORF in major depressive patients as compared
with controls, while Risch et a! (1986) reported
a lower OH response 15 minutes after ORF injection
in five major depressive patients as compared
with eleven age- and gender-matched normal
subjects.
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